Pyroglutamylated amyloid beta-protein (pE-Aβ)

Pyroglutamylated amyloid beta-protein refers to an N-terminally truncated form of the classic amyloid β-peptide, where an initial glutamic acid residue is cyclized into a pyroglutamate moiety. This modification occurs at positions such as E3 or E11, resulting in variants like pE 3–40/42 or pE 11–40/42. These modified peptides accumulate abundantly within the core regions of senile plaques found in brains affected by Alzheimer's disease. The presence of a pyroglutamate group increases resistance to proteolytic degradation and alters peptide conformation—favoring more flexible structures compared to wild-type Aβ—and promotes prion-like seeding activity that can drive further misfolding and aggregation into neurotoxic oligomers rather than less harmful fibrils[2][3]. This makes them particularly important both as pathological agents and therapeutic targets within neurodegeneration research.

Other names

Pyroglutamate-modified amyloid betaN-terminally truncated amyloid betapE-Aβ (pyroglutamylated Aβ)AβpE3 (amyloid beta starting at position 3 with pyroglutamate modification)PyroGlu-Aβ

Drugs targeting this molecule typically aim to: - Inhibit aggregation or promote clearance of pyroglutamylated Aβ species. - Block prion-like conformational seeding that leads to toxic oligomer formation. These mechanisms are inferred from its role in promoting toxic aggregates distinct from unmodified Aβ peptides[2].